Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
publication is digital, 24/7 - the sec its signed off by the final reviewer it will be released
also remember , no more `hold the front page ` they can and do publish 24/7 , and once the review is complete I imagine there are legal drivers that mean they really do want to get it out there sharpish and off their hands so to speak for fear of leaks etc especially in there have been many many doctors reviewing ..
extrooper - that doesn't mean what you think it means ..
DD -
The journal paper is in peer review , believe me nothing else matters.
When the review is complete the journal will publish asap , even for a prestigious journal TLD on a ph3 15 year trial is a scoop, they will get it out post haste..
GMP for Sawstone is required but its not that big a deal getting certified go on the CMS website their are hundreds of certified sites , but I agree if we were to get certified tomorrow for instance yes we`d get a good jump in PPS but its irrelevant to the timing of data via the journal .
Danish Dude ,
for heavens sake , what are you talking about ?..how many times have we been told `data via major journal release` ... everything else is white noise ..
No point in arguing with you Biotecinvestor , you seemingly made your mind up long ago to accept anything and everything the organ grinder and his monkey drip feed us long ago ...
Our volumes have exploded , thats due to warrant sellers converting and dumping, its as simple as that , if that wasnt happening then we`d probably be bobbing along in the $1.20's ...and time decay on journal release date may well have seen a few nice gains ...
AND...re his `Biotech markets being horrible`...well
since 1st May 21 :
XBI is 8.6% below the average price
NWBO is 39% below the average price
Innes is now as disingenuous and unreliable as the company buffoon Goldman
..and not a mention of warrants sellers dumping their hideously discounted shares .... which is probably 80% of the selling ...
and his equally disingenuous reply failing to mention Institutions cant buy on the OTC Mickey friggin Mouse exchange even if they wanted to :
"Sometimes big investors wait till they see results and then load up. They don't try to pick bottoms. Evrybody has their own methodology."
F
Agreed 100%
RSI 26 buy buy buy ( sorry ...but I`m right )
We will rip through $1.20 on GMP
Link please ??
Todays XBI is recovering , we should also ... somewhat
..Not sure if this has already been posted :
https://www.bracknellnews.co.uk/news/19672721.towies-james-argent-among-celebs-help-save-boys-life/
Meet end points 1 & 2 = Floor $4
Meet end points 1 - 4 = Circa $5-$8
Meet all end points = Circa $7 - $10
JV, Licensing = $10+
Any news on applications already having been made = $10++
Best news I`ve read recently is that Senti thinks the process is now out of their (utterly inept) hands ...
agreed , some answers as to what could have happened in our case but as always for every answer up comes another question ..
RSI 29 get long ..
Endpoint Change Comparison
BREAKING NEWS
07:11 11/22/21
Imara announces primary endpoint change in Ardent Phase 2b trial of IMR-687
Imara announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine, IMR-687, in patients with sickle cell disease, SCD, based on the recommendation of the U.S. Food and Drug Administration. Imara requested feedback from the FDA on the draft statistical analysis plan, SAP, for the Ardent trial in which fetal hemoglobin, HbF, response was the primary endpoint and annualized rate of vaso-occlusive crises, VOCs, was the key secondary endpoint. In reviewing the Ardent draft SAP and prior to any database lock for analysis, the FDA recommended that Imara change the primary endpoint to be annualized rate of VOCs. HbF response will continue to be evaluated as a key secondary endpoint. The endpoint revisions do not affect the conduct of the trial or operational aspects of the study. As part of its recommendation, the FDA suggested further interactions regarding the revised SAP and engagement on the potential of the current program for regulatory decision-making. "We welcome the FDA's recommendations and are in the process of changing the primary endpoint of the Ardent trial to be annualized rate of VOCs and moving HbF response to be a key secondary endpoint," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "A reduction in VOC rate is an established approval endpoint, and we are engaging the FDA further on this and related topics, including possible streamlined paths to registration." Ballal continued, "In light of this endpoint revision, the previously planned fourth quarter interim analysis will no longer occur. That interim analysis had been designed to have a focus on safety and pharmacodynamic biomarkers, including HbF, but did not include a review of VOCs. The first review of data from the Ardent trial, including annualized VOC rate, will be conducted when all subjects have completed assessment at Week 24 or terminated early, and is planned for the first quarter of 2022, subject to our upcoming discussions with the FDA. Final data analysis from the Ardent trial remains on track for the second half of 2022. In June 2021, we reported promising data from our Phase 2a and open label extension clinical trials in SCD that demonstrated reduced annualized rates of VOCs in patients treated with tovinontrine versus placebo. We expect to present updated 12-month VOC data from our ongoing Phase 2a open label extension clinical trial at the American Society of Hematology Annual Meeting in December 2021."
RSI closed at 31 Friday
If you can …Just keep buying
RSI 36 BUY
RSI 37 last time we were here we saw a 20 cents rally in one session
Great narrative , thanks
Very Good ... :)
..did you ever see `Goldman..The Movie`
`Fake shares, Overstock , blockchain , cusip, hundreds of millions of illegal shorts , Donald Trump, Jimmy Cagney Cofer Black & George Raft, Crusade , no more dilution , UK 40 patients a month (May 2020)..... and soooo much more ... coming to a cinema near you .. `
...And the antidote for low prices is ...
....low prices
..add that to the fact even for NEJM releasing the TLD of a 13 year $700m ground breaking, SOC crushing trial is a coup even for them.. maybe even a first ..
...when our `friendlies` stop the warrant related selling and as attention moves to SNO possibilities the pps will easily get 1.50's ++.
Just look at the run up to our ASM day in May where we ripped through all chart points and added 65 cents in 3 sessions.
Anyone got even a rough idea what the composition is of the current outstanding shares are ?
ie 500m held by officers 200m by lenders ( Bigger etc )
Basically looking for how many retail to gauge liquidity post data
Thanks
what ... theres a country thats not USA ...
UTTER RUBBISH DOESNT APPLY HERE
He has a huge underlying position , he is taking FREE CASH that we gave him off the table whilst maintaining his underlying ..
Under these circumstances he didn't sign the NDA he cash say and do as he friggin pleases ..
duplicate
UTTER RUBBISH DOESNT APPLY HERE
He has a huge underlying position , he is taking FREE CASH that we gave him off the table whilst maintaining his underlying ..
Under these circumstances he didn't sign the NDA he cash say and do as he friggin pleases ..
UTTER RUBBISH DOESNT APPLY HERE
He has a huge underlying position , he is taking FREE CASH that we gave him off the table whilst maintaining his underlying ..
Under these circumstances he didn't sign the NDA he cash say and do as he friggin pleases ..
Do what you friggin like...
ZZZZZZZZZzzzzzzzzzzzzz...........
Thats interesting , so please tell me why would promoting on social media and selling part of his stock land him in jail ... I`m all ears ???
Utter piffle .. bub
OK find me a takeover by large pharma in the $Bn's
where they used shares ... you are making a fool of yourself .